Egalet Reports Q3 Results, Offers ARYMO ER Updates

Egalet Corp EGLT lost $1.10 per share in its third quarter and missed estimates by $0.20 per share.
Revenue of $4.7 million beat by $0.1 million.
Company highlighted FDA Advisory Committee's recommended approval of ARYMO ER during the quarter.
Company also highlighted closing of $40 million in financing during the quarter.
Cash and marketable securities totaled $101.2 million at the end of the quarter.
CEO Bob Radie expects the FDA to finalize review of ARYMO ER in time for a potential launch in the first quarter of 2017.

Posted In:

Earnings News Health Care General ARYMO ER Bob Radie Egalet

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.